T

Twist Bioscience

1066 employees

Twist Bioscience is a synthetic DNA production for specialty chemical compounds and drug development.

Investor insights

Sectors invested in

single cell analysis1
Biotechnology1
Pharmaceutical1
Life Science1
antibodies1
microfluidics1
stem cells1
lab-on-a-chip1
biopharmaceutical1
genome editing1
oncology1
droplets1
biologics1
life sciences1
immunotherapy1
pharmaceutical1
cells1
biotechnology1
cell therapies1
immunology1

Funding rounds participated in

$1.3M sweet spot round size

Most of their 1 investments are in rounds between $1.3M and $1.3M

Basic info

Industry

biotechnology research

Sectors

Biotechnology
CRISPR
Exome Sequencing
Target Enrichmentt
Oligonucleotides
DNA Data Storage
Pharmaceutical
Core Exome
DNA Sequencing
Drug Discovery
Variant Libraries
Gene Synthesis
Life Sciences
CRISPR Libraries
Synthetic Biology
Chemical
Health Care
Primers
DNA
Synthetic DNA
Next Gen Sequencing
NGS
Life Science

Date founded

2013

Investments made

S

Sphere Fluidics Limited raised $1.3M on July 17, 2017

Investors: Innovate UK, The University of Edinburgh and Twist Bioscience

Funding rounds raised

Total raised

$61M

from 23 investors over 23 rounds

T

Twist Bioscience raised $27M on June 14, 2017

Investors: Ditch Plains Capital Management LP, Reinet Advisors Jersey Limited, Bay City Capital and Biomatics Capital

T

Twist Bioscience raised $33M on March 27, 2017

Investors: Dentsu Ventures and Asset Management Ventures

T

Twist Bioscience raised $61M on January 19, 2016

Investors: GoldenArc Capital, Paladin Capital Group, Foresite Capital, Illumina Ventures and +ND Capital

T

Twist Bioscience raised $37M on June 9, 2015

Investors: Paladin Capital Group, ARCH Venture Partners, Asset Management Ventures, Foresite Capital and +ND Capital

T

Twist Bioscience raised $26M on May 27, 2014

Investors: Paladin Capital Group, +ND Capital, ARCH Venture Partners and Asset Management Ventures

T

Twist Bioscience raised $9.1M on February 10, 2014

Investors: Paladin Capital Group, Asset Management Ventures and ARCH Venture Partners

FAQ